Press releaseGlobe Newswire
Atea Pharmaceuticals
AVIR · NASDAQ
$4.47+$0.075 (+1.71%)TodayMarket closed ·
Prev close $4.39
Latest news
- NewsVandana Singh
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
- Press releaseGlobe Newswire
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
- Press releaseGlobe Newswire
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
- Press releaseGlobe Newswire
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
- Press releaseGlobe Newswire
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
- Press releaseGlobe Newswire
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
- News
Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
- Press releaseGlobe Newswire
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
- News
Earnings Scheduled For May 12, 2026
- Press releaseBusiness Wire
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO
- Press releaseGlobe Newswire
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- News
Earnings Scheduled For March 5, 2026
- News
Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings
- Press releaseBusiness Wire
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman
- News
Earnings Scheduled For November 12, 2025
- News
Atea Pharmaceuticals Earnings Preview
- News
Earnings Scheduled For August 7, 2025
- Press releaseGlobe Newswire
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
- Press releaseBusiness Wire
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors
- NewsVandana Singh
Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial
- Press releaseBusiness Wire
Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process
- NewsVandana Singh
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
- NewsAvi Kapoor
Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.